Professional Documents
Culture Documents
Punim Magjistrature
Punim Magjistrature
_____________________________________________________
sha tator , 2006
PRIS HT INË
HYRJE
Rezulatatet e këtij punimi janë shfaqur në mënyrë tabelare dhe grafike për çdo
parametër të përcaktuar biokimikë dhe hematologjikë.
Të dhënat e fituara ( vlerat mesatare të përqendrimit apo numrit) të çdo
parametri janë shfaqur në tabela dhe grafikone duke krahasuar :
-vlerat mesatare të grupit të kontrollit me vlerat e grupit të pacientëve të trajtuar
gjashtë muaj,
-vlerat mesatare të grupit të kontrollit me vlerat e grupit të pacientëve të trajtuar
tetë muaj me antituberkulotikë, si dhe
-vlerat mesatare të pacientëve të trajtuar gjashtë muaj me vlerat e pacientëve të
trajtuar tetë muaj me këto barna
PËRFUNDIMET
fjalët bosht:
Tuberkulozi Pulmonar (TBC-P), antitubekulotikët, parametrat biokimikë dhe
hematologjikë, pacientët me trajtim 6-mujor dhe pacientët me trajtim 8-mujor
me barna antituberkulare.
SUM MAR Y
5. Brodie MJ, Bobbis AR, Dollery CT et al. Rifampicin and vitamin D metabolism. Clin
Pharmacol Ther. 1980; 27: 810 – 814
6. Dickinson DS, Bailey WC, Hirschowitz BI et al. Risk factors for isoniazid (INH)-
induced liver dysfunction. J. Clin Gastroenterol. 3: 271- 279, 1981
7. Khanna BK, Gupta VP. Ethambutol induced hiperuricemia. Tubercle 1984; 195-9
10. Ellad GA, Haslam RM. Observations on the reduction of the renal elimination of
urate in man caused by the administration of pyrazinamide.
Tubercle 1976; 57; 97-103
11. Girling DI. The role of pyrazinamide in in primary chemotherapy for pulmonary
tuberculosis. Tubercle 1984: 65;1-4
12. Gulliford M, Mackay AD, & Prowse K: Cholestatic jaundice caused by ethambutol.
Br Med J 1986; 292: 866
13. Jenkins, PF et al. Neutropenia with each standard antituberculosis drug in some
patients Br. Med J 1980: 280 1069-70
14. Williams SE, Wardman AG, Taylor GA, et al. Long term study of the effect of
rifampicin and isoniazid on vitamin D metabolism. Tubercle. 1985;66:49-5
19. Young DS, Effects of Drugs on Clinical Laboratory Tests. Volume one and two.
AACC Pres. Fifth edition; 2000
20. Tietz, NW, Clinical Guide to Laboratory Tests, WB. Sounders Company, 3 rd ed.
Philadelphia 1995
21. Weichselbaum TE : An accurate and rapid method for the determination of proteins in
small amounts of blood serum and plasma. Amer J Clin Path 16:40 (1946)
22. Trinder, P., Determination of glucose in blood using glucose oxidase with an
alternative oxygen acceptor. Ann. Clin. Biochem 6:24 (1969)
24. Teuscher, A., Richterich, P., Schweiz med. Wschr. 101, 345 and 390 (1971)
25. Richmond,W., Preparation and properties of a cholesterol oxidase from Nocardia sp.
And its application to the enzymatic assay of total cholesterol in serum Clin. Chem. 19,
35 (1973)
26. Roeschlau, P., et. al., Enzymatic determination of total cholesterol in serum J.Clin
Chem. Clin. Biochem 12, 403 (1974)
27. Jacobs, NJ, VanDemark, PJ Arch. Biochem. Biophys. 88, 250- 255 (1960).
28. Schetter, G., Nüssel, E., Arb. Med. Soz. Med. Präv. Med. 10, 25 (1975)
31. Van den Bergh, A.A.H., and Müller , PM, Biochem Z 77, 90 (1916)
33. Thefeld, L et al. Dtsch. Med. Wschr 98, 380 – 384 (1973)
34. Barham, D., Trinder, P., An improved colour reagent for the determination of blood
glucose by the oxidase system Analy st 97, 142 (1972)
35. Jaffe MZ: Über den Niederschlag, welchen Pikrinsaure in normalem Harn erzeugt
and über eine Reaction des Kreatinins.
Zeitschrift Für Physologische Chemie 10: 391-400 (1886)
37. Schirmeister, J et al Dtsch. Med. Wschr 89, 1018 and 1640 (1964)
43. Synopsis der Leber Krankheiten : H. Wallnöfer E. Schmidt und. W.F. Georg
Thieme Verlag. Stuttgart (1974)
47. Persijn JP, van der Slike. W. A new method for the determination of gamma-
glutamyltransferase in serum J. Clin. Chem. Clin. Biochem 14, 421-7 (1976)
51. Pines A, Raafat M, Siddiqui GM. Rifampicin and ethambutol in the treatment of drug
resistant and far advanced pulmonary tuberculosis. J Ir Med Ass, 63, 82 (1970)
52. Hansten PD. Drug interactions. Philadelphia PA, Lea & Febiger (1973)
53. Letellier, G., Desjarlais, F. Analytical interference of drugs in clinical chemistry;
Study of twenty drugs on seven different instruments. Clin Biochem 1985; 18: 345 –
351
54. Meyler L, Herxheimer A (eds). Side Effects of Drugs. The Hague , Exerpta Medica,
5 (1996)
55. Sunderman FW . Drug interference in clinical biochemistry. Crit Rev Clin Lab Sci,
1, 427 (1970)
56. Van Scoy R, Wilkowske CJ. Antituberculous agents. Mayo Clin Proc 1987; 62:1129
– 1136
57. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics 4th edition,
New York NY, Mac Millan and Co (1970)
58. Huubuch A. Results of the multicenter study with Tinaquant albumin in urine. Wien
Klin Wschr, 103. suppl 189, 23-29 (1991)
59. Ama Council on Drugs. Ama Drug Evaluations. Chicago IL, American Medical
Association (1973)
63. Lubran M. The effects of drugs on Laboratory values. Med Clin North Am, 53, 211
(1969)
64. Miles Inc. Product Insert for Multistix 10 SG Reagent Strips. Elkhart, IN (2/92)
65. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to Antituberculosis Therapy:
Clinical Profile and Reintroduction of Therapy. J Clin Gastroenterol. 1996; 22 : 211
– 214
66. Hansten, PD: Drug Interactions. Philadelphia, PA: Lea and Febiger 1971
67. Acocella G, Billing BH. Effect of drugs on the hepatic transport of bilirubin. In
Therapeutic Agents and Liver. Oxford Blackwell (1965)
68. Galeazzi R et al. Rifampin induced elevation of serum bile acids in man. Dr Dis Sci
25, 108-112 (1980)
71. Walker PC. Neonatal bilirubin toxicity. A review of kernicterus and the implications
of drug – induced bilirubin displacement. Clin Pharmakin, 13,26-50(1987)
73. Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia due to Ethambutol. N
Engl J Med, 286, 761-2 (1972)
78. Steele TH. Control of uric acid extretion. N Eng J Med. 284, 1193 (1971)
79. Du Pont aca package insert for total bilirubin. Du Pont, Willmington DE (3/87)
81. Philip IR. Untoward effects of antimicrobial drugs: prevention and control.
Postgard med, 50, 193 (1971)
82. Pfizer Inc. Manufacturer’s literature on Streptomycin. New York, NY 10017 (1995)
83. Singh HP, Herbert MA, Gault MH. Effect of some drugs on chemical laboratory
values as determined by the Technicon SMAC 12-60. Clin. Chem 18, 137 (1972)
84. Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology
72: 1348-1353, 1977
85. O’ Brien RJ, Long MW, Cross FS et al. Hepatotoxicity from isoniazid and rifampin
among children treated for tuberculosis. Pediatrics, 72, 491-499 (1983)
86. Byrd RB, Horn BR, Grigs GA, Solomon DA: Isoniazid chemoprophylaxis:
Association with detection and incidence of liver toxicity. Arch. Intern Med 1977;137:
1130-3
87. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of
various durations of isoniazid preventive therapy for tuberculosis: five years of follow-
up in the IUAT trial. Bull World Health Organ 1982;60,555-564
89. Alexander MR, Louie SG & Guernsey BG. Isoniazid – Associated Hepatitis Clin.
Pharm. 1982, 1, 148 – 153
90. Hellstrom PE, Repo UK, Mattson K. New drugs in tuberculosis. Drugs, 1, 349 (1971)
91. Linna O, Uhari M. Hepatotoxicity of rifampicin and izoniasid in children treated for
tuberculosis. Eur J Pediatris 134, 227-229 (1980)
92. Millar JW. Rifampicine induced porphyria cutanea tarda. BR J Dis Chest 1980;
74:405 –408
96. Philips I. Clinical uses and control of rifampicin and clindamycin J Clin
Pathol, 24,410 (1971)
97. Claibrone RA, Dutt AK. Isoniazid – induced pure red cell aplasia.
Am Rev Respir Dis. 1985; 131:947 – 9. Pub.Med.
99. Dacie JV. The Haemolytic Aneamias part IV. New York NY, Grune and
Stratton (1967)